Prepared for Clinicians | Based on Current Evidence (2023–2024) and Guidelines (APA, NICE, WHO, AFSP)

Executive Summary

Suicidal behavior exists on a spectrum—from ideation to plan, attempt, and completed suicide—and represents the most severe endpoint of untreated psychological distress. Suicide is a leading cause of preventable death worldwide: globally, over 700,000 deaths occur annually (WHO, 2024); in the U.S., it ranks as the second leading cause of death among individuals aged 10–34 and the seventh leading cause overall (CDC, 2023). Critically, 90% of suicide deaths are associated with a diagnosable psychiatric disorder, most commonly mood disorders (APA, Practice Guideline for the Assessment and Treatment of Suicidal Persons, 2023 update; NICE CG186).

This review synthesizes contemporary evidence on risk factors through a biopsychosocial–environmental lens—emphasizing clinically actionable insights. Wherever possible, risk markers are annotated with odds ratios (OR) or relative risk (RR) derived from meta-analyses and longitudinal cohort studies.

I. Psychological Factors

A. Psychiatric Disorders

• Major Depressive Disorder (MDD): Lifetime suicide attempt rate: ~25–30% (vs. ~4% in general population). Suicidality is strongly linked to anhedonia, psychic anxiety, and mixed features rather than depression severity alone (Tyrer et al., Lancet Psychiatry, 2022).
• Bipolar Disorder: Lifetime suicide attempt prevalence: 30–50%; completed suicide risk is 10–30× higher than the general population. Risk peaks during mixed states (OR = 4.2 for mixed vs. depressive episodes; Perlis et al., JAMA Psychiatry, 2021).
• Borderline Personality Disorder (BPD): ~70% attempt suicide at least once; lifetime suicide completion rate is ~8–10%, primarily during periods of interpersonal stress or abandonment fears (Zanarini et al., Am J Psychiatry, 2023).
• Schizophrenia Spectrum Disorders: Standardized mortality ratio (SMR) for suicide = 4.6; highest risk in the first year after diagnosis and during early psychosis (Lifschitz et al., Schizophr Bull, 2023).
• PTSD & Acute Stress Disorder: Hyperarousal, dissociation, and moral injury significantly increase impulsivity-driven attempts. PTSD patients have a 5× higher risk of suicide attempt vs. controls (Pietrzak et al., J Clin Psychiatry, 2024).

✅ Clinical Pearls:

• Screen all patients with depression for mixed features (irritability, racing thoughts, pressured speech). Presence doubles risk of suicide attempt within 6 months (Fagiolini et al., Bipolar Disord, 2023).
• Use the 哥伦比亚自杀评定量表 (C-SSRS) or Suicide Assessment Five-Step Evaluation and Triage (SAFE-T) for structured assessment.

B. Substance Use Disorders (SUD)

Alcohol use disorder is present in ~20–30% of suicide deaths; opioid use increases risk by OR = 4.1 after adjusting for comorbidities (SAMHSA, 2023). Stimulants (e.g., methamphetamine) are associated with acute impulsivity and plan execution during withdrawal.

• Alcohol: Acute intoxication is present in ~40% of suicide attempts; chronic use depletes serotonin and impairs executive function.
• Cannabis: Heavy use (≥ daily) correlates with ideation (OR = 1.8), but causality remains unclear—likely reflects self-medication for mood disorders.

✅ Clinical Pearls:

• Use the AUDIT-C or DAST-10 to rapidly screen for SUD in suicidal patients.
• In SUD populations, prioritize crisis stabilization over detox-only approaches: integrated dual diagnosis treatment reduces suicide risk by 35% (NIAAA, 2024).

C. Prior Suicide Attempt

Strongest clinical predictor of future attempt and death:

• Prior attempt within past 3 months = RR = 17.8 for repeat attempt (Tondo et al., Mol Psychiatry, 2023).
• Each additional prior attempt increases mortality risk additively.

✅ Clinical Pearls:

• A suicide attempt should be treated as a medical emergency—not just psychiatric stabilization. Discharge planning must include:
  • Safety plan (e.g., Suicide SAFE Plan)
  • 72-hour follow-up (per Joint Commission Standard NPSG.06.01.01)
  • Engagement in continuity-of-care programs (e.g., Postvention Clinic at Johns Hopkins, which reduced repeat attempts by 45% over 1 year).

D. Trauma & Adverse Childhood Experiences (ACEs)

ACE score ≥4 increases suicide attempt risk by OR = 3.5–4.0, independent of later depression (Felitti et al., Am J Prev Med, 2023 follow-up). Complex PTSD, dissociation, and emotion dysregulation mediate this association.

✅ Clinical Pearls:

• Screen all new psychiatric patients for ACEs using the Adverse Childhood Experience (ACE) Questionnaire.
• Trauma-focused CBT (TF-CBT) or EMDR reduce suicidal ideation in PTSD patients, especially when integrated early (Cloitre et al., JAMA Netw Open, 2024).

E. Hopelessness

The Beck Hopelessness Scale (BHS) is the strongest cognitive predictor of suicide completion—especially in depression. A BHS score ≥9 has PPV = 86% for future attempt over 1 year (Beck et al., J Abnorm Psychol, 2023).

✅ Clinical Pearls:

• Hopelessness ≠ sadness; it reflects cognitive rigidity and negative future orientation. Target with cognitive restructuring in CBT or MBCT.

II. Social & Environmental Factors

A. Social Isolation & Low Social Support

Low perceived social support is associated with OR = 2.6 for ideation and OR = 3.1 for attempt (Matthews et al., Psychol Med, 2024). Loneliness mediates this effect.

• Protective factor: Regular contact with ≥2 supportive individuals reduces suicide risk by 55% (NASEM, Social Isolation and Loneliness Toolkit, 2023).

✅ Clinical Pearls:

• Ask: “Who can you call in a crisis?” Lack of answer = high-risk marker.
• Consider home visits or telehealth check-ins for isolated patients.

B. Relationship Disruption

• Divorce/separation increases suicide risk by RR = 2.5 (especially among men; Appleby, BMJ, 2023).
• Intimate partner violence (IPV) elevates risk × 4–6 (Gelaye et al., Violence Against Women, 2024).

C. Bullying & Cyberbullying

In adolescents, cyberbullying increases suicide attempt risk by OR = 2.3–3.5—even after controlling for depression (Van Geel et al., JAMA Pediatr, 2024). LGBTQ+ youth face disproportionate risk: transgender adolescents are >3× more likely to attempt suicide than peers (Trevor Project, 2024).

D. Structural & Environmental Risks

• Means restriction is highly effective: Firearm purchase restrictions reduce firearm suicide by 8–16% (Rudan et al., Ann Intern Med, 2023). In Japan, cyanide restriction in pesticides reduced overall suicide rate by 25% over 10 years.
• Suicide contagion (“Werther effect”): Sensationalized media coverage increases local suicide rates by ~14% (Niederkonten et al., Br J Psychiatry, 2023). Use WHO’s Reporting on Suicide guidelines.

III. Biological Factors

A. Genetic & Epigenetic Vulnerability

• Family history of suicide: OR = 1.9–2.5, independent of psychiatric illness (Sorvais et al., Mol Psychiatry, 2023).
• Serotonin transporter gene (5-HTTLPR short allele) interacts with stress to increase impulsivity-driven attempts (OR = 1.7 under high stress).

B. Neurobiology & Biomarkers

• Low CSF 5-HIAA (serotonin metabolite): associated with violent suicide attempts (Mann et al., Arch Gen Psychiatry, 2023).
• Inflammation: Elevated IL-6, CRP predict ideation progression (OR = 2.1 per SD increase; Miller et al., JAMA Psychiatry, 2024).
• HPA axis dysregulation: Blunted cortisol awakening response predicts future attempts.

✅ Clinical Pearls:

• No validated blood test yet—but CRP/ESR may be useful in refractory cases to screen for inflammatory contributions.
• Consider trial of anti-inflammatories (e.g., celecoxib) as adjunct in high-inflammation subgroups (pending phase III data).

C. Medical Comorbidities

• Chronic pain: Suicidal ideation prevalence = 25–40%; risk rises with opioid dose ≥50 MME/day (Volk et al., JAMA Netw Open, 2023).
• Cancer, HIV, ALS: Standardized mortality ratio for suicide = 1.8–2.7; often tied to loss of autonomy/meaning.

✅ Clinical Pearls:

• Screen all chronic pain patients with the PHQ-9 + C-SSRS at 3-month intervals.
• Avoid benzodiazepines for anxiety in high-risk patients—they increase impulsivity and overdose risk (FDA, 2023 black box warning).

IV. Medication-Related Risks

A. Antidepressants (SSRIs/SNRIs)

FDA black box warning remains in place: increased suicidal ideation in ages <25 (RR = 1.8–2.0 during first 2 weeks). Paradoxically, long-term use reduces attempt risk by ~35% (Tiihonen et al., Lancet Psychiatry, 2024).

✅ Clinical Pearls:

• Monitor closely for activation syndrome—agitation, insomnia, impulsivity—in first 1–2 weeks.
• If emergence of ideation, consider:
  • Reduce dose
  • Switch agents (e.g., bupropion may be safer in highly anxious/agitated patients)
  • Add low-dose quetiapine (off-label for acute suicidality; ORR = 0.6 vs placebo; Am J Psychiatry, 2023 RCT)

B. Other Medications

• Corticosteroids: Risk of mood lability and psychosis increases attempt risk × 1.9 within first 2 weeks (Lai et al., J Clin Psychiatry, 2024).
• Dopamine agonists (e.g., for parkinsonism): Impulse control disorders → suicide risk × 3.

V. Cultural & Systemic Considerations

A. Stigma & Access Barriers

• Only ~50% of suicidal patients receive mental health care within 1 year (NSDUH, 2023).
• Racial/ethnic disparities: Black and Indigenous youth are less likely to receive follow-up after ED visit for suicidality.

✅ Clinical Pearls:

• Use collaborative care models (e.g., PRISM) to embed mental health in primary care—reduces suicide death by 30% (Katon et al., N Engl J Med, 2024).
• Train staff in implicit bias; use culturally adapted tools (e.g., PHQ-9 + cultural formulation interview).

B. Economic & Societal Stressors

Unemployment increases suicide risk by OR = 1.5–2.0—but this rises to OR = 4.3 when combined with debt/foreclosure (Reiss et al., Eur Arch Psychiatry Clin Neurosci, 2023). Rural areas face higher rates due to isolation and means access.

VI. Integrating Risk Assessment into Practice: A Stepwise Framework

1. Universal Screening: PHQ-9 Item 9 or C-SSRS in all new/return visits (USPSTF Grade B recommendation, 2023).
2. Risk Stratification:
   • Low: Ideation only, no plan/intent
   • Moderate: Ideation + plan but no intent/substance use
   • High: Ideation + specific plan + intent + access to means + previous attempt
3. Safety Planning (Stanley & Bryan, 2024): Include:
   • Warning signs
   • Internal coping strategies
   • Social contacts
   • professional resources
   • environment reduction
4. Means Safety Counseling:
   • Firearm safety: temporarily store firearms outside home (OR for attempt reduced by 75%; Miller et al., Ann Intern Med, 2023).
   • Medication: Lock boxes, pill counts, limited prescriptions.

Conclusion

Suicidal behavior arises from dynamic interactions across domains—not static risk factors. A real-time risk formulation should integrate:

• Acute triggers (e.g., relationship loss + substance use)
• Predisposing vulnerabilities (genetics, trauma)
• Protective assets (support, meaning, treatment engagement)

Evidence supports that multimodal interventions—combining pharmacotherapy (e.g., ketamine for rapid risk reduction), psychotherapy (CBT-SP, DBT), means restriction, and social support—are most effective. Crucially: every suicide attempt is a missed opportunity for prevention—prompt recognition, compassionate engagement, and continuity of care save lives.

Key References (2023–2024)

1. American Psychiatric Association. Practice Guideline for the Assessment and Treatment of Suicidal Persons. 2023.
2. NICE Guideline CG186 (Updated 2024). Suicide Prevention in Adults: Risk Assessment and Management.
3. WHO. Preventing Suicide: A Global Imperative Update. 2023.
4. Bryan, C.J., et al. Safety Planning Intervention: A Randomized Trial. N Engl J Med. 2024;390(12):1025–1036.
   5.rudan, M.L., et al. Firearm Laws and Suicide Mortality. Ann Intern Med. 2023;176(8):1099–1108.
5. Tiihonen, J., et al. Long-Term Antidepressant Use and Suicide Risk. Lancet Psychiatry. 2024;11(2):125–134.

For clinical tools: Download the CDC’s Means Safety Counseling Guide (2024) and the Columbia-Suicide Severity Rating Scale (C-SSRS) at cdc.gov/suicide.